Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Secondary polycythemia

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44337   clinical trials with a EudraCT protocol, of which   7367   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: Secondary polycythemia. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2018-001908-11 Sponsor Protocol Number: RG_16-148 Start Date*: 2022-09-12
    Sponsor Name:UNIVERSITY OF BIRMINGHAM
    Full Title: A phase III, randomised, open-label, Multicenter International Trial comparing ruxolitinib with either HydRoxycarbamIDe or interferon Alpha as first line ThErapyfor high risk polycythemia vera
    Medical condition: Myeloproliferative neoplasm (MPN), specifically Polycythaemia Vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-020807-57 Sponsor Protocol Number: CINC424B2301 Start Date*: 2011-02-08
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase III study of Efficacy and Safety in Polycythemia vera subjects who are resistant to or intolerant of hydroxyurea: JAK iNhibitor INC424 tablets verSus bEst ...
    Medical condition: Polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GB (Completed) IT (Completed) NL (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-012784-34 Sponsor Protocol Number: 384/09 Start Date*: 2009-07-08
    Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
    Full Title: STUDY OF HYDROXYUREA MECHANISMS OF ACTION ON LEUKOCYTE ACTIVATION IN PATIENTS WITH CHRONIC MYELOPROLIFERATIVE SYNDROMES.
    Medical condition: MYELOPROLIFERATIVE SYNDROMES
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015493 LLT
    9.1 10036057 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003583-31 Sponsor Protocol Number: CINC424B2401 Start Date*: 2014-02-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: Randomized, open label, multicenter phase IIIb study evaluating the efficacy and safety of ruxolitinib versus best available therapy in patients with polycythemia vera who are hydroxyurea resistant...
    Medical condition: Polycythemia vera resistant or intolerant to hydroxyurea
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed) HU (Completed) BE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-005259-18 Sponsor Protocol Number: PROUD-PV Start Date*: 2013-08-15
    Sponsor Name:AOP Orphan Pharmaceuticals AG
    Full Title: A randomized, open-label, multicenter, controlled, parallel arm, phase III study assessing the efficacy and safety of AOP2014 vs. Hydroxyurea in patients with Polycythemia Vera
    Medical condition: Polycythemia Vera
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) IT (Completed) SK (Completed) AT (Completed) BG (Completed) DE (Completed) PL (Completed) ES (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2013-004105-11 Sponsor Protocol Number: GS-US-354-0101 Start Date*: 2014-07-04
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2, Open-label, Randomized Study to Evaluate Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia
    Medical condition: subjects with either polycythemia vera (PV) or essential thrombocythemia (ET)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004652-15 Sponsor Protocol Number: 29BRC20.0263 Start Date*: 2021-06-08
    Sponsor Name:CHRU de Brest
    Full Title: AVAJAK: Apixaban/rivaroxaban Versus Aspirin for primary prevention of thrombo-embolic complications in JAK2V617F-positive myelo-proliferative neoplasms
    Medical condition: Myelo-proliferative neoplasms including essential thrombocythemia, Polycythemia Vera, Prefibrotic myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015494 Essential thrombocythemia LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003295-12 Sponsor Protocol Number: 15022013 Start Date*: 2013-10-31
    Sponsor Name:Roskilde University Hospital
    Full Title: Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    18.1 100000004864 10036061 Polycythemia vera LLT
    18.1 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2007-005306-49 Sponsor Protocol Number: MK-0683-092 Start Date*: 2008-09-03
    Sponsor Name:Department of Haematology, Herlev Hospital, University of Copenhagen
    Full Title: A Phase II Study of Vorinostat in Patients with Polycythaemia Vera and Essential Thrombocythaemia
    Medical condition: patients with polycythaemia vera or essential thrombocythaemia or myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036057 Polycythaemia vera LLT
    9.1 10015493 Essential thrombocythaemia LLT
    12.1 10028537 Myelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) SE (Completed) NL (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-005279-18 Sponsor Protocol Number: RG_11-164 Start Date*: 2012-02-08
    Sponsor Name:University of Birmingham
    Full Title: A RandoMised study of best Available therapy versus JAK Inhibition in patients with high risk Polycythaemia Vera or Essential Thrombocythaemia who are resistant or intolerant to HydroxyCarbamide.
    Medical condition: Polycythaemia vera Essential Thrombocythaemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2010-019501-41 Sponsor Protocol Number: MPD-RC112 Start Date*: 2012-02-15
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia
    Medical condition: High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing) SE (Ongoing) GB (Completed) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-004476-36 Sponsor Protocol Number: GS-US-352-1154 Start Date*: 2014-12-11
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: Open-label Study to Assess the Long-term Safety and Efficacy of Momelotinib in Subjects with Primary Myelofibrosis, Post polycythemia Vera Myelofibrosis, Post essential Thrombocythemia Myelofibros...
    Medical condition: subjects with either primary myelofibrosis (PMF) or post polycythemia vera myelofibrosis or post essential thrombocythemia myelofibrosis (post-PV / ET MF) or polycythemia vera (PV) or essential thr...
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-001012-56 Sponsor Protocol Number: I3X-MC-JHTB Start Date*: 2012-08-30
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 2 Study of LY2784544 in Patients with Myeloproliferative Neoplasms
    Medical condition: Myeloproliferative neoplasms (MPNs), myelofibrosis, essential thrombocythemia, and polycythemia vera
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036061 Polycythemia vera LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) SE (Completed) AT (Trial now transitioned) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001672-38 Sponsor Protocol Number: KRT-232-102 Start Date*: 2018-12-10
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: A Two-Part, Randomized, Open-label, Multicenter, Phase 2a/2b Study of the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared to Ruxolitinib in Patients with Phlebotomy-Dependent Polycythemi...
    Medical condition: Phlebotomy-dependent polycythemia vera. Polycythemia Vera (PV) is classified as a myeloproliferative neoplasm (MPN).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10036061 Polycythemia vera LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Prematurely Ended) ES (Ongoing) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003276-39 Sponsor Protocol Number: 09072012 Start Date*: 2013-01-09
    Sponsor Name:Hæmatologisk afdeling, Roskilde Sygehus, Region Sjælland
    Full Title: Investigation of the value of Iron and Bonemarrow stimulation in differential diagnostic of Polycythemia Vera and Essential Thrombocytosis
    Medical condition: Polycythemia Vera Essential thrombocytosis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10022958 Iron and trace metal metabolism disorders HLGT
    15.0 10005329 - Blood and lymphatic system disorders 10029355 Neutropenias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002318-37 Sponsor Protocol Number: INCB18424-357 Start Date*: 2012-11-06
    Sponsor Name:Incyte Corporation
    Full Title: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
    Medical condition: Polycythemia Vera
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) IT (Completed) ES (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003009-31 Sponsor Protocol Number: HH007 Start Date*: 2022-12-23
    Sponsor Name:Zealand University Hospital, dept. of Haematology
    Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis
    Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077465 Myeloproliferative neoplasm PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-000583-18 Sponsor Protocol Number: SRA-MMB-301 Start Date*: 2020-01-07
    Sponsor Name:Sierra Oncology, Inc.
    Full Title: A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera...
    Medical condition: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028538 Myelofibrosis with myelometaplasia LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074689 Post polycythemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074690 Post essential thrombocythemia myelofibrosis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074691 Post polycythaemia vera myelofibrosis LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10074692 Post essential thrombocythaemia myelofibrosis LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077161 Primary myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) SE (Completed) DK (Completed) FR (Completed) CZ (Completed) ES (Restarted) PL (Completed) HU (Completed) AT (Completed) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-003411-21 Sponsor Protocol Number: FEDR-MF-002 Start Date*: 2019-05-14
    Sponsor Name:Impact Biomedicines, Inc., a Wholly Owned Subsidiary of Celgene Corporation
    Full Title: A Phase 3, multicenter, open-label, randomized study to evaluate the efficacy and safety of fedratinib compared to best available therapy in subjects with DIPSS - intermediate or high-risk primary ...
    Medical condition: Primary myelofibrosis, post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) GB (GB - no longer in EU/EEA) ES (Ongoing) IE (Trial now transitioned) NL (Completed) AT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002253-30 Sponsor Protocol Number: SVT-RUXO#2012 Start Date*: 2012-10-04
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI FIRENZE
    Full Title: A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Medical condition: splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 22 08:13:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA